Overcoming Access Barriers to Antibiotics
This blog was originally published on CDDEP website on 15 July 2019. Somewhat perversely, antibiotic overuse exists side-by-side with lack of access to such medicines in today’s world. While we are aware of the consequences of drug-resistant bacterial infections, it is less well known that there are millions of people in low- and middle-income countries...
Read moreAdvancing Health-Related SDGs in Africa Through Private Sector Collaborations
This blog was originally published on Health Policy Watch on 25 October 2019. As the World Health Summit opens Sunday in Berlin, one of the key themes running through the conference will be how industry, government and civil society leaders can collaborate more effectively to build strong health institutions – with a particular focus on...
Read moreProgress in discovering new antibiotics is imperative
This article was originally published (in German) in the print edition of Frankfurter Allgemeine Zeitung (FAZ) on October 29, 2019. Progress in discovering new antibiotics is imperative Boosting R&D to fight superbugs: getting the risk-reward ratio right Fifty years ago, the global health community thought it had won the war against infectious diseases through antibiotics....
Read moreFive Questions to …. Dr. Lembit Rägo
This year IFPMA is hosting its 10th Asia Regulatory Conference (ARC2020) in Kuala Lumpur. The Council for International Organizations of Medical Sciences (CIOMS) is represented in the conference Advisory Board by Dr Lembit Rägo, its Secretary General. IFPMA sat down with Dr Rägo to discuss CIOMS’s activities, future of the biopharmaceutical industry and the future...
Read more5 Questions to …. five leading biopharmaceutical company CEOs and top executives on the COVID-19 Pandemic
This was originally published in Pharma Boardroom on Wednesday, 1 April, 2020. The CEOs and top executives, David Ricks, Chairman and Chief Executive Officer, Eli Lilly & Co and IFPMA President, Severin Schwan, Chief Executive Officer, Roche, Paul Stoffels, Chief Scientific Officer, Johnson & Johnson, David Loew, Executive Vice-President, Sanofi Pasteur and Rajeev Venkayya, President,...
Read more5 Recent Developments Contributing to Vaccine R&D
This was originally published on Innovation.org on Tuesday, 26 May, 2020. Throughout recent history, vaccines represent the most impactful public health advance, helping to prevent the spread of infectious diseases and, in many places, eliminating some of the most devastating conditions. As communities around the world continue to grapple with the impact of COVID-19, vaccines and what...
Read moreCreating a New Generation of Antibiotics webinar – opportunity to explain how pharma has stepped to the plate
I recently participated in Chatham House Webinar: Creating a New Generation of Antibiotics. It was a great opportunity for me to tell Jim O’ Neill, how little over a year ago, he played a role in speeding up industry action on AMR – something I had decided the IFPMA should engage on when I took...
Read moreHow vaccinations help protect all ages of the population
This oped was originally published on Media Planet Value of Vaccines Q4 2020 Campaign on 10 December 2020 The COVID-19 pandemic has reminded us how vulnerable the world is in the face of deadly pathogens. Vaccines have been an essential tool offering protection from diseases like diphtheria, tetanus, pneumonia, and polio, diseases that once harmed...
Read moreCOVID-19 diagnostics, treatments and vaccines: Progress achieved in 2020 and insights into 2021 and beyond
Last week, IFPMA hosted the fifth and last CEO COVID-19 media briefing of 2020 with CEOs and top executives from Eli Lilly and Company, Johnson & Johnson, Pfizer and Roche. I joined the CEOs as they shared their take on progress achieved in 2020 and insights into 2021 and beyond. With this blog, I wanted...
Read moreInvesting in chronic care: Sustainable financing models for type 1 diabetes
The discovery of insulin in 1921 changed type 1 diabetes from a death sentence to a condition that can be controlled and managed successfully. Yet a hundred years later, children still die from diabetes, especially in low- and middle-income countries (LMICs).
Read more